Doug Janzen

Founder & Managing Director, Northview LifeSciences

Doug Janzen has been involved in the life sciences industry for the past 19 years. He is currently the Founder and President of NorthView Ventures, an organization which invests in and provides strategic advisory services to a number of technology companies. Previously, Doug was President and CEO of Cardiome Pharma, a NASDAQ listed drug development company that raised over $300 million from investors, and completed over $1 billion in licensing deals during his tenure. In 2010, Cardiome’s lead product, Brinavess, was approved and launched in Europe by Merck. Prior to that, he was an investment banker with Cormark Securities, acting as Managing Director of Life Sciences. Doug is Past Chair of LifeSciences BC, has served as a Director with Biotech Canada and currently sits as a Director on a number of public and private boards. He is a past winner of Business in Vancouver’s Top 40 Under 40 Qward, and has recently co-founded and leads Aequus Pharmaceuticals, a company focused on the reformulation and novel delivery of approved anti-psychotics.